There can’t be many people in the UK who enjoyed a £2.5 million pay rise this year – but that’s what GlaxoSmithKline boss Emma Walmsley got after a strong year for sales.
Increasing interest in real-world evidence (RWE) across all stakeholder groups has the industry buzzing about its current role in clinical trials and the potential impact of expanded use.
Bristol-Myers Squibb has unveiled long-term results from its immunotherapy Opdivo in the most common form of kidney cancer, showing that more than a quarter of patients were alive after fiv
